European Commission Approves Stribild

Gilead Sciences Inc. said Tuesday that the European Commission has approved Stribild as a new, single tablet regimen for treatment of HIV-1 infection in adults. Stribild is also approved in the U.S., Canada, Australia, South Korea, Japan and Turkey. Stribild contains four Gilead compounds in a complete once-daily, single tablet regimen. Stribild can be used for adults who are antiretroviral treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. The… Read more

US HIV vaccine trial shut down

A study testing the latest experimental HIV vaccine has been stopped after an independent review board found that it did not prevent HIV infection and did not decrease the amount of HIV in the blood. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced that they will stop giving doses of this experimental vaccine. The trial, which began in 2009 is the most recent in a line of unsuccessful HIV vaccine studies…. Read more

Dolutegravir To Get FDA Priority Review

ViiV Healthcare Ltd., a joint venture of GlaxoSmithKline Plc and two other drugmakers, said its experimental HIV medicine dolutegravir will get a speedier review by the U.S. Food and Drug Administration. A regulatory decision is scheduled for Aug. 17 after Viiv submitted an application on Dec. 17. The FDA gave dolutegravir priority review status, which is granted to drugs that have the potential to offer significant improvement over existing therapies or where no adequate treatment exists, the company said. The… Read more

STUDY: Undetectable Viral Load Essentially Eliminates Transmission Risk

According to a recent review of multiple studies, heterosexual serodiscordant couples have an almost non-existent risk of HIV transmission if the HIV-positive partner has an undetectable viral load as a consequence of successful antiretroviral (ARV) therapy, the National AIDS Treatment Advocacy Policy (NATAP) reports. Presenting their findings at the Third International Workshop on HIV and Women in Toronto, researchers pooled data from six different studies of serodiscordant heterosexual couples, including the famous HPTN 052, which found a 96 percent risk reduction due to ARV therapy.

Read More

amFAR: The Next Generation of AIDS Researchers

amFAR, The Foundation for AIDS Research, announced its sixth round of Mathilde Krim Fellowships in Basic Biomedical Research, designed to support the work of young HIV/AIDS researchers. The new Krim Fellows—Christine Durand, M.D., of Johns Hopkins University School of Medicine; Lucie Etienne, Ph.D., of the Fred Hutchinson Cancer Research Center in Seattle; Alon Herschhorn, Ph.D., of the Dana-Farber Cancer Institute; and Leopold Kong, Ph.D., of the Scripps Research Institute in La Jolla, CA—will each receive $125,000.

Read More

amfAR: Gay Men, MSM Key to Successful HIV/AIDS Response

The Lancet-hosted symposium at the 19th International AIDS Conference. “Today we need to acknowledge that we have failed in too many places to provide even the most basic services to gay men. In much of the world, they remain hidden, stigmatized, and susceptible to blackmail if they disclose their sexual lives,” said amfAR Vice President and Director of Public Policy Chris Collins during the 19th International AIDS Conference, which took place in late July in Washington, D.C. “HIV epidemics in 2012 are severe… Read more

Back to Top